Ultragenyx Pharmaceutical | RARE - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Immunic USD 120.38M 21.73M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Kyowa Hakko Kirin JPY 523.59M 99K 2026-06
MacroGenics USD 63.56M 241K 2026-03
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.55M 50K 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06